Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.

Dexcom issues new recall for CGM apps due to safety risk—users urged to update immediately
The FDA has categorized this as a Class I recall. If patients update their phone or watch apps as needed, they can continue to use these devices like normal.
Why all heart patients should be vaccinated against the flu, COVID-19, RSV
The American College of Cardiology has shared new recommendations highlighting the protective benefits of a variety of vaccines. The new guidance also examines how to speak with patients who are hesitant to be vaccinated.
First study of its kind to focus on new therapy for hypoplastic left heart syndrome
The new trial represents a potential breakthrough in the treatment of one of the most devastating congenital heart defects.
Real-world data link semaglutide, tirzepatide to improved heart failure outcomes
GLP-1 drugs have been taking the United States by storm in recent years. According to a new study of more than 90,000 patients, some of these medications can also make a big impact on reducing adverse heart failure outcomes.
Beta blockers ‘have no effect’ on heart attack patients
One researcher described the study's findings as "one of the most significant advances in heart attack treatment in decades.”

LAAC or DOACs? How treatment strategies for AFib impact long-term outcomes

The new analysis provided an update on data from the PRAGUE-17 trial.

DOACs underprescribed among high-risk AFib patients

The study found that frail patients with AFib are less likely to be treated with DOAC therapy.

Metoprolol demonstrates value as a treatment for obstructive hypertrophic cardiomyopathy

The small study, published in the Journal of the American College of Cardiology, compared patient outcomes associated with metoprolol and a placebo.

DOACs outperform VKAs among cardiac amyloidosis patients with HF, AFib

Outcomes from patients prescribed apixaban, rivaroxaban or dabigatran were compared with outcomes from patients given warfarin.

Generic statin options can save the US $11.9B per year

The study tracked five generic statins: atorvastatin, rosuvastatin, simvastatin, lovastatin and pravastatin.

Q&A: Cleveland Clinic cardiologist details the past, present and future of drug-eluting stents

Amar Krishnaswamy, MD, shared his thoughts on this important technology in an exclusive interview.

AFib patients able to safely transition from warfarin to a DOAC

The new analysis, published in the Journal of the American Heart Association, explored what happens with AFib patients shift their anticoagulant strategy.

Black, Hispanic AFib patients less likely to start anticoagulant therapy, new VA study finds

Researchers wrote that they hope their findings can help guide the creation of policies that reduce disparities in care for AFib patients.

Pharmaceutics

Dexcom issues new recall for CGM apps due to safety risk—users urged to update immediately

Why all heart patients should be vaccinated against the flu, COVID-19, RSV

First study of its kind to focus on new therapy for hypoplastic left heart syndrome

Real-world data link semaglutide, tirzepatide to improved heart failure outcomes

Beta blockers ‘have no effect’ on heart attack patients